NB‐UVB vs PUVA
Withdrawals due to adverse events · atopic eczema
1 finding from 1 review
- no estimate extracted1 study · 20 participantsVery low
Findings
What do systematic reviews say?
891 questions · 902 findings · 317 reviews
No studies found 210 · 23.3%GRADE not reported 56 · 6.2%Very low 236 · 26.2%Low 220 · 24.4%Moderate 146 · 16.2%High 34 · 3.8%
Fluoroquinolones vs beta‐lactams
Serious adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes serious adverse events clinical criteria compared with beta‐lactams (very low certainty).
1 finding from 1 review
- RR 10.9 [0.61, 194.82]1 study · 221 participantsVery low
Bae: AZT/3TC/NVP vs d4T/3TC/NVP
Maternal Grade 3/4 Severe Adverse Events · HIV‐Infected Pregnant Women With CD4<350
It is very uncertain whether jamisse (What to Start): AZT/3TC/NVP changes maternal Grade 3/4 Severe Adverse Events compared with d4T/3TC/NVP (very low certainty).
1 finding from 1 review
- Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes onlyRR 1.58 [0.6, 4.12]1 study · 146 participantsVery low
Bae: AZT/3TC/NVP vs AZT/3TC/NVP
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected pregnant women
It is very uncertain whether jamisse (When to Start): AZT/3TC/NVP for CD4 250‐350 changes maternal Grade 3/4 Severe Adverse Events compared with AZT/3TC/NVP (very low certainty).
1 finding from 1 review
- Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes onlyRR 1.18 [0.47, 2.97]1 study · 146 participantsVery low
Bae: AZT/3TC/NVP vs AZT/3TC/NVP
Maternal Grade 3/4 Severe Adverse Events · HIV‐1 Infected Pregnant Women Who Have CD4>200 Compared with Those Who Have CD4<200 Cells/mm3
It is very uncertain whether phanuphak: AZT/3TC/NVP (PMTCT) changes maternal Grade 3/4 Severe Adverse Events compared with AZT/3TC/NVP (ART) (very low certainty).
1 finding from 1 review
- Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes onlyRR 1.98 [0.65, 6.03]1 study · 244 participantsVery low
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes maternal Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
- Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes onlyRR 1.09 [0.77, 1.53]1 study · 824 participantsVery low
Unfractionated heparin vs low molecular weight heparin
Treatment cessation due to adverse events · CRRT
Unfractionated heparin showed no clear difference in treatment cessation due to adverse events compared with low molecular weight heparin (low certainty).
1 finding from 1 review
- Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes onlyRR 0.29 [0.02, 3.53]2 studies · 77 participantsLow
Unfractionated heparin vs no pharmacological anticoagulation
Treatment cessation due to adverse events · CRRT
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Citrate vs unfractionated heparin
Treatment cessation due to adverse events · CRRT
Citrate showed no clear difference in treatment cessation due to adverse events compared with unfractionated heparin (low certainty).
1 finding from 1 review
- Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes onlyRR 0.47 [0.15, 1.49]3 studies · 412 participantsLow
Summary of findings for multi‐dose nasal decongestant vs placebo
Secondary outcome: all adverse eventsOral · adult patients with the common cold
Summary of findings for multi‐dose nasal decongestant showed no clear difference in secondary outcome: all adverse eventsOral compared with placebo (low certainty).
1 finding from 1 review
- OR 0.95 [0.65, 1.39]6 studies · 1134 participantsLow
Low‐intensity pulsed ultrasound vs control
Adverse events ‐ total of adverse events (Skin irritation) · acute fractures in adults; included studies assessed effects in complete upper limb fractures (distal radius, clavicle, scaphoid,…
It is very uncertain whether low‐intensity pulsed ultrasound changes adverse events Reported as skin irritation compared with control (very low certainty).
1 finding from 1 review
- Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes onlyRR 0.94 [0.06, 14.65]1 study · 101 participantsVery low
Carisbamate vs placebo
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.8 [0.78, 4.17]4 studies · 2211 participantsVery low
IPL (with/without MGX) vs no treatment/sham
Incidence of adverse events at 3 months of · people with meibomian gland dysfunction
1 finding from 1 review
- Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Clobazam vs placebo
Withdrawals due to adverse events · patients with drug‐resistant epilepsy
1 finding from 1 review
- no estimate extracted2 studies · 150 participantsVery low
CBT plus standard care vs usual care
Adverse events experienced at short or long term ‐ general adverse events 24 weeks' · patients with schizophrenia
It is very uncertain whether COMPARISON 1: CBT+ STANDARD CARE changes adverse events: General: any adverse event compared with STANDARD CARE ALONE (very low certainty).
1 finding from 1 review
- Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia 2018 · Cochrane Headline outcomes onlyRR 0.44 [0.27, 0.72]2 studies · 146 participantsVery low
Intervention not reported
Participants (n) reported adverse events ( · patients with Rheumatoid arthritis
The intervention showed no clear difference in participants (n) reported adverse events ( (low certainty).
1 finding from 1 review
- RR 1.36 [0.49, 3.82]1 study · 23 participantsLow
Intervention not reported
Participants (n) reported adverse events ( · patients with treating rheumatoid arthritis
The intervention showed no clear difference in participants (n) reported adverse events ( (moderate certainty).
1 finding from 1 review
- RR 4.24 [0.78, 22.99]2 studies · 61 participantsModerate
LNG‐IUS vs oral progestogen (norethisterone acetate)
Adverse events (spotting at 3 and 6 months) · women with uterine fibroids
1 finding from 1 review
- Progestogens or progestogen‐releasing intrauterine systems for uterine fibroids (other than preoperative medical… 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 45 participantsVery low
Intervention not reported
Severe adverse events: raised transaminases · antiretroviral‐naïve individuals
The intervention leads to lower severe adverse events: raised transaminases (high certainty).
1 finding from 1 review
- Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes onlyRR 0.52 [0.35, 0.78]3 studies · 1299 participantsHigh
Intervention not reported
Severe adverse events: raised triglycerides · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised triglycerides (low certainty).
1 finding from 1 review
- Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes onlyRR 1.1 [0.39, 3.13]2 studies · 1071 participantsLow